Foreign Patentee’s Licensing Efforts Satisfy “Commercial Activity” Exception To Federal Sovereign Immunities Act
Client Alert | 1 min read | 07.24.06
In Intel Corp. v. Commonwealth Sci. and Indus. Research Org. (Nos. 06-1032, -1040, July 14, 2006), the Federal Circuit finds the CSIRO's acts of obtaining a U.S. patent and attempting to generate royalty income by licensing the patent were not activities peculiar to a sovereign state under the Federal Sovereign Immunities Act (“FSIA”), but commercial activities that a private entity would engage in.
CSIRO, Australia's national science agency, had attempted to license its patent to certain U.S. companies, who subsequently filed declaratory-judgment actions for non-infringement and invalidity after the respective licensing offers expired. CSIRO moved to dismiss the actions for lack of subject matter jurisdiction, claiming immunity under the FSIA. The Federal Circuit panel rejects CSIRO's argument that the “commercial activity” exception to the FSIA would apply only if its patent license negotiations resulted in a fully-executed, binding contract.
The Federal Circuit also rejects CSIRO's argument that the declaratory-judgment suits are not “based upon” the alleged commercial activity as required under the FSIA. These declaratory-judgment suits, says the panel, are "based on" CSIRO's commercial acts of obtaining and asserting a U.S. patent and, to prevail, plaintiffs must prove that CSIRO attempted to enforce its patent against them. CSIRO's representations as to the scope and validity of the patent during license negotiations are also central to plaintiff's claims.
Insights
Client Alert | 5 min read | 08.21.26
FTC Proposes Enforcement Policy Statement on Personalized Pricing: What Businesses Need to Know
On August 19, 2026, the Federal Trade Commission (FTC) announced a proposed Enforcement Policy Statement on personalized pricing — the practice of companies using consumers’ personal data to set individualized prices, discounts, coupons, or other incentives. The proposed statement, which is open for public comment for 30 days following publication in the Federal Register, marks a major step up in the FTC’s focus on data-driven pricing strategies and puts businesses across industries on notice that undisclosed or inadequately disclosed personalized pricing will not be tolerated. Importantly, while the proposed statement is not a binding legal requirement and does not create new legal obligations, it serves as an enforcement warning that the FTC is prepared to use its existing enforcement authority under Section 5 of the FTC Act (Section 5) and is also a potential harbinger of rulemaking. Businesses that engage in — or are considering — personalized pricing should carefully assess their disclosure practices and data collection procedures against the standards articulated in this statement.
Client Alert | 7 min read | 08.19.26
CMS’s Final Rule Bans Federal Medicaid Funding for Youth Gender-Affirming Care
Client Alert | 2 min read | 08.19.26
